Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus Biosciences by Year
Arcus Biosciences — Research and development (R&D) expense ($M) ($M)
Gilead Sciences Arcus Biosciences: $523M in FY2025, up 16.7% from a year earlier.
Latest, FY2025
523
Period ended Dec 31, 2025
Change on a year earlier
+16.7%
448 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Research and development (R&D) expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 523 | +16.7% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2024 | Dec 31, 2024 | 448 | +31.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 340 | +18.1% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 288 | +12.1% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 257 | +61.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 159 | +102.5% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 78.5 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-rd-exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.